Singapore’s Nuevocor raises $45M Series B for Novel...

added blog Health

2025-05-09 14:00:50 -

Singapore’s Nuevocor raises $45M Series B for Novel Cardiomyopathy therapy development

Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, has announced the successful completion of $45 million Series B financing. The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund,...

0 Comments 0 Shares 72 Views 0 Reviews